Literature DB >> 17526950

Interleukin-6 production and deregulation of the hypothalamic-pituitary-adrenal axis in patients with major depressive disorders.

Derek Humphreys1, Liana Schlesinger, Marcelo Lopez, A Verónica Araya.   

Abstract

The present study was designed to determine whether an association exists between HPA activity and cytokine production in major depression (MD). In 9 patients with MD and 11 control subjects of both sexes, all drug-free, activity of the HPA axis was evaluated by circadian rhythm of plasma cortisol, 24-h free urinary cortisol, an overnight 1 mg dexamethasone suppression test, and an oCRF stimulation test. Spontaneous and LPS-stimulated production of IL-1beta, IL-6, and TNFalpha by peripheral blood mononuclear cells were also determined. We found a significantly elevated spontaneous production of IL-6 in patients with MD (3541.2 +/- 726.8 vs 380.4 +/- 77.5 pg/mL in controls, p < 0.05), while LPS-stimulated production was significantly lower in patients than in control subjects (19,867.7 +/- 3649.2 vs 33,142.2 +/- 15,47.2 pg/mL, p < 0.05). The adrenocorticotropic hormone response to oCRF, evaluated as the area under the curve (AUCACTH) was significantly lower in patients than in control subjects (p = 0.02). A positive correlation between AUCACTH and LPS-stimulated IL-6 secretion was observed in patients with MD (r = 0.75, p < 0.05) but not in controls. These findings suggest that the activation of the inflammatory response described in depression might be associated with long-term hyperactivity of the HPA axis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17526950     DOI: 10.1007/s12020-006-0016-1

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.925


  40 in total

1.  Consistent reduction of ACTH responses to stimulation with CRH, vasopressin and hypoglycaemia in patients with major depression.

Authors:  R G Kathol; R S Jaeckle; J F Lopez; W H Meller
Journal:  Br J Psychiatry       Date:  1989-10       Impact factor: 9.319

2.  Bio-social origins of depression in the community. Interactions between social adversity, cortisol and serotonin neurotransmission.

Authors:  Paul L Strickland; J F William Deakin; Carol Percival; Joanne Dixon; Richard A Gater; David P Goldberg
Journal:  Br J Psychiatry       Date:  2002-02       Impact factor: 9.319

Review 3.  Noradrenergic sympathetic neural interactions with the immune system: structure and function.

Authors:  D L Felten; S Y Felten; D L Bellinger; S L Carlson; K D Ackerman; K S Madden; J A Olschowki; S Livnat
Journal:  Immunol Rev       Date:  1987-12       Impact factor: 12.988

4.  Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity.

Authors:  A N Vgontzas; D A Papanicolaou; E O Bixler; A Kales; K Tyson; G P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  1997-05       Impact factor: 5.958

5.  Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study.

Authors:  R H Straub; H W Hense; T Andus; J Schölmerich; G A Riegger; H Schunkert
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

6.  Characterization and functional significance of glucocorticoid receptors in patients with major depression: modulation by antidepressant treatment.

Authors:  G Calfa; S Kademian; D Ceschin; G Vega; G A Rabinovich; M Volosin
Journal:  Psychoneuroendocrinology       Date:  2003-07       Impact factor: 4.905

Review 7.  The role of corticotropin-releasing factor in depression and anxiety disorders.

Authors:  L Arborelius; M J Owens; P M Plotsky; C B Nemeroff
Journal:  J Endocrinol       Date:  1999-01       Impact factor: 4.286

8.  Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression.

Authors:  M Maes; H Y Meltzer; E Bosmans; R Bergmans; E Vandoolaeghe; R Ranjan; R Desnyder
Journal:  J Affect Disord       Date:  1995-08-18       Impact factor: 4.839

9.  Resistance to suppression by dexamethasone of plasma 11-O.H.C.S. levels in severe depressive illness.

Authors:  B J Carroll; F I Martin; B Davies
Journal:  Br Med J       Date:  1968-08-03

Review 10.  Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis.

Authors:  P M Plotsky; M J Owens; C B Nemeroff
Journal:  Psychiatr Clin North Am       Date:  1998-06
View more
  8 in total

1.  Antidepression medication improves quality of life in elderly patients with benign prostatic hyperplasia and depression.

Authors:  Lina Ma; Xiaoling Zhao; Huizhen Liu; Hong Zhu; Wei Yang; Yuying Qian; Jieyu Wang; Ming Feng; Yun Li
Journal:  Int J Clin Exp Med       Date:  2015-03-15

2.  Expansion of CD11b+Ly6Ghigh and CD11b+CD49d+ myeloid cells with suppressive potential in mice with chronic inflammation and light-at-night-induced circadian disruption.

Authors:  Yuliya V Perfilyeva; Nurshat Abdolla; Yekaterina O Ostapchuk; Raikhan Tleulieva; Vladimir C Krasnoshtanov; Nikolai N Belyaev
Journal:  Inflamm Res       Date:  2017-04-28       Impact factor: 4.575

3.  Differential association of circadian genes with mood disorders: CRY1 and NPAS2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder.

Authors:  Virginia Soria; Erika Martínez-Amorós; Geòrgia Escaramís; Joaquín Valero; Rosario Pérez-Egea; Cecilia García; Alfonso Gutiérrez-Zotes; Dolors Puigdemont; Mònica Bayés; José M Crespo; Lourdes Martorell; Elisabet Vilella; Antonio Labad; Julio Vallejo; Víctor Pérez; José M Menchón; Xavier Estivill; Mònica Gratacòs; Mikel Urretavizcaya
Journal:  Neuropsychopharmacology       Date:  2010-01-13       Impact factor: 7.853

4.  HIV and symptoms of depression are independently associated with impaired glucocorticoid signaling.

Authors:  Mandakh Bekhbat; C Christina Mehta; Sean D Kelly; Aimee Vester; Ighovwerha Ofotokun; Jennifer Felger; Gina Wingood; Kathryn Anastos; Deborah R Gustafson; Seble Kassaye; Joel Milam; Bradley Aouizerat; Kathleen Weber; Elizabeth T Golub; Michelle Floris Moore; Ralph Diclemente; Margaret Fischl; Mirjam-Colette Kempf; Pauline Maki; Gretchen N Neigh
Journal:  Psychoneuroendocrinology       Date:  2018-06-18       Impact factor: 4.905

Review 5.  Therapeutic Strategies for Treatment of Inflammation-related Depression.

Authors:  Miroslav Adzic; Zeljka Brkic; Milos Mitic; Ester Francija; Milica J Jovicic; Jelena Radulovic; Nadja P Maric
Journal:  Curr Neuropharmacol       Date:  2018-01-30       Impact factor: 7.363

6.  Immunological effects of behavioral activation with exercise in major depression: an exploratory randomized controlled trial.

Authors:  F Euteneuer; K Dannehl; A Del Rey; H Engler; M Schedlowski; W Rief
Journal:  Transl Psychiatry       Date:  2017-05-16       Impact factor: 6.222

7.  Glucocorticoid Resistance: Is It a Requisite for Increased Cytokine Production in Depression? A Systematic Review and Meta-Analysis.

Authors:  Andrew J Perrin; Mark A Horowitz; Jacob Roelofs; Patricia A Zunszain; Carmine M Pariante
Journal:  Front Psychiatry       Date:  2019-06-28       Impact factor: 4.157

8.  The Emerging Role of the Double-Edged Impact of Arachidonic Acid- Derived Eicosanoids in the Neuroinflammatory Background of Depression.

Authors:  Magdalena Regulska; Magdalena Szuster-Głuszczak; Ewa Trojan; Monika Leśkiewicz; Agnieszka Basta-Kaim
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.